The achievement represents progress for the collaboration, which was launched in September 2010 to develop G protein coupled receptor (GPCR)-targeted therapeutic compounds utilizing Anchor’s proprietary pepducin technology.
Pepducins are lipidated peptides designed to be allosteric modulators for G protein coupled receptor (GPCR) targets, especially those intractable to current approaches.
During this initial research phase, Anchor pepducins demonstrated to have in-vivo efficacy in a relevant model and satisfactorily achieved other criteria necessary to earn further research funding support.
Anchor said that these results triggered an undisclosed cash payment to Anchor.